CAS 905281-76-7
C19H18N4O2
MW 334.38
Purity: 99%

KP Hoeflich et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009, 69(7), 3042-3051.

H Wong et al. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2, 3-dihydro-1H-inden-5-yl]-3- (pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J. Pharmacol. Exp. Ther. 2009, 329(1), 360-367

Recommended Products
GDC0941
GDC0449
GDC0879
Gefitinib
Abiraterone(CB-7598)
ABT-263
ABT-737
ABT-888
AZD1152-HQPA
BEZ-235
BIBF1120
PTC-124
SGX-523
BIBW2992
Bortezomib
CP-690550
Elvitegravir
FTY720
LBH-589
LY2140023(LY404039)
LY294002
NVP-AUY922
NVP-TAE684
PD-0325901
PD-153035 hydrochloride
PF-04217903
Vandetanib
Vatalanib,Dihydrochloride Salt
VX-680 (MK-0457)(Tozasertib)
ZSTK-474
BIX02188
AZD2281
A-769662
Rivaroxaban
Resveratrol
Prasugrel
Eltrombopag
LY450139
AZ-23
VX-950(Telaprevir)
Calcitriol
Calcifediol;monohydrate
R-406
CUDC-101
CP-724714
AG-1478 hydrochloride
AS-1413(Amonafide)
1H-Benzimidazole,1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)-
A-966492